Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials
Cisplatin played an important role in the treatment of gastric cancer (GC). Oxaliplatin has been shown to be at least as effective as cisplatin for GC, with less toxicity and a better tolerability profile. We performed a meta-analysis to compare the efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of GC.
Databases of CNKI, CBM, VIP, Wanfang, PubMed, Embase, Cochrane Library were searched for eligible literatures from their establishments to November 2018. Randomized controlled trials that compared the efficacy and safety of oxaliplatin-based regimen with that of cisplatin-based regimen in the treatment of GC were included. Statistical analyses were calculated using RevMan 5.3 software.
Seven randomized controlled trials including 2297 patients were included. Compared with cisplatin-based regimen intervention in GC, oxaliplatin-based regimen treatment was able to significantly improve the partial response rate (OR = 1.26, 95% CI 1.07–1.49; p = 0.007), disease progression rate (OR = 0.41, 95% CI 0.25–0.66; p = 0.0002) and 1-year survival (OR = 1.25, 95% CI 1.00–1.56; p = 0.05). The toxicities of hematopoietic system were significantly higher in cisplatin-based regimen group (OR = 0.6, 95% CI 0.46–0.79; p = 0.0002), while oxaliplatin-based regimen group had higher neurosensory toxicity (OR = 2.21, 95% CI 1.52–3.21; p < 0.0001), In addition, gastrointestinal toxicity was similar between the two groups (OR = 1.01, 95% CI 0.5–2.01; p = 0.27).
Compared with cisplatin-based regimen, oxaliplatin-based regimen treatment has an obvious advantage in patients with GC with acceptable tolerance.
KeywordsGastric cancer Oxaliplatin Cisplatin Chemotherapy
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they had no conflict of interest in preparing this article.
- 2.Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19(8):1893–1907. https://doi.org/10.1158/1055-9965.epi-10-0437
- 10.Popov I, Radosevic-Jelic L, Jezdic S et al (2008) Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J BUON 13(4):505–511Google Scholar
- 15.Kim YS, Sym SJ, Park SH et al (2014) A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemother Pharmacol 73(1):163–169. https://doi.org/10.1007/s00280-013-2334-3 CrossRefGoogle Scholar
- 16.Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. https://doi.org/10.1200/jco.2007.13.9378 CrossRefGoogle Scholar
- 18.Jianqun L, Yungen Z (2014) clinical study of oxaliplatin combined with 5-fluorouracil and calcium folinate for chemotherapy in patients with advanced gastric cancer. Clin Med Eng 21(11):1447–1448Google Scholar
- 19.Wenyi W, yang X (2008) Clinical observation of cisplatin, oxaliplatin and paclitaxel in the treatment of advanced gastric cancer. Chin J Coal Ind Med 11(11):1726–1727Google Scholar
- 21.Kouroussis C, Souglakos J, Kakolyris S et al (2001) Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61(1):36–41. https://doi.org/10.1159/000055350 CrossRefGoogle Scholar
- 22.Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211. https://doi.org/10.1200/jco.2006.08.6652 CrossRefGoogle Scholar
- 26.Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483. https://doi.org/10.1200/jco.2002.07.061 CrossRefGoogle Scholar
- 27.Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055–4061. https://doi.org/10.1158/1078-0432.ccr-03-0666 CrossRefGoogle Scholar